| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| atropine sulfate monohydrate | Injection, solution | 1.2 mg/mL | Resolved | Available | Manufacturing | 9/10/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Anticipated | Available | Manufacturing | 9/10/2024 |
| trandolapril | Capsule | 2 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 9/10/2024 |
| isosorbide dinitrate | Tablet, uncoated | 5 mg | Current | Limited Availability | Manufacturing | 9/10/2024 |
| morphine hydrochloride trihydrate | Oral Liquid, solution | 1 mg/mL | Resolved | Available | Commercial Changes / Commercial viability | 9/10/2024 |
| risperidone | Tablet, film coated | 1 mg | Current | Unavailable | Manufacturing | 9/10/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 9/10/2024 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Anticipated | Available | Manufacturing | 9/10/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Unavailable | Manufacturing | 9/10/2024 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Anticipated | Available | Manufacturing | 9/10/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 9/10/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 9/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 9/10/2024 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 1.819 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 9/10/2024 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Resolved | Available | Manufacturing | 9/10/2024 |
| lacosamide | Tablet, film coated | 100 mg | Resolved | Available | Manufacturing | 9/10/2024 |
| codeine phosphate hemihydrate~doxylamine succinate~paracetamol | Tablet, uncoated | 30 mg~5 mg~450 mg | Resolved | Available | Manufacturing | 9/10/2024 |
| amlodipine besilate~hydrochlorothiazide~olmesartan medoxomil | Tablet, film coated | 6.95 mg~12.5 mg~40 mg | Current | Unavailable | Manufacturing | 9/10/2024 |
| calcium chloride dihydrate~magnesium chloride hexahydrate~sodium lactate~glucose~sodium chloride | Solution, irrigation | 183 mg/L~50.8 mg/L~4.48 g/L~15 g/L~5.38 g/L | Current | Limited Availability | Manufacturing | 8/10/2024 |
| calcium chloride dihydrate~glucose~sodium lactate~magnesium chloride hexahydrate~sodium chloride | Solution, irrigation | 183 mg/L~25 g/L~4.48 g/L~50.8 mg/L~5.38 g/L | Current | Limited Availability | Manufacturing | 8/10/2024 |
| levetiracetam | Tablet, film coated | 500 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 8/10/2024 |
| codeine phosphate hemihydrate~doxylamine succinate~paracetamol | Tablet, uncoated | 10 mg~5.1 mg~500 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| paclitaxel | Injection, concentrated | 300 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| milrinone | Injection, concentrated | 10 mg | Current | Limited Availability | Manufacturing | 8/10/2024 |
| azithromycin dihydrate | Tablet, film coated | 524 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| cisplatin | Injection, concentrated | 1 mg/mL | Anticipated | Available | Manufacturing | 8/10/2024 |
| lacosamide | Tablet, film coated | 150 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| gliclazide | Tablet, uncoated | 80 mg | Resolved | Available | Unexpected increase in consumer demand | 8/10/2024 |
| ketorolac trometamol | Injection, solution | 30 mg/mL | Resolved | Available | Manufacturing | 8/10/2024 |
| phentermine hydrochloride | Tablet, modified release | 49.7 mg | Current | Limited Availability | Manufacturing | 8/10/2024 |
| carmustine | Injection, powder for | 100 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| methotrexate | Tablet | 10 mg | Current | Limited Availability | Manufacturing | 8/10/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 109 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 54.5 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| sitagliptin hydrochloride monohydrate | Tablet, film coated | 27.25 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| Adalimumab | Injection, solution | 40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 8/10/2024 |
| levothyroxine sodium | Tablet, uncoated | .05 mg | Current | Unavailable | Manufacturing | 8/10/2024 |
| cisplatin | Injection, solution | 1 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 8/10/2024 |
| verapamil hydrochloride | Tablet, modified release | 180 mg | Current | Limited Availability | Manufacturing | 8/10/2024 |
| rifabutin | Capsule, hard | 150 mg | Resolved | Available | Manufacturing | 8/10/2024 |
| rizatriptan benzoate | Wafer | 14.53 mg | Resolved | Available | Manufacturing | 8/10/2024 |
| pamidronate disodium | Injection, concentrated | 6 mg | Current | Limited Availability | Manufacturing | 8/10/2024 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Resolved | Available | Manufacturing | 8/10/2024 |
| pegcetacoplan | Injection, solution | 1080 mg | Anticipated | Available | Manufacturing | 7/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.7 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/10/2024 |
| medronic acid | Injection, powder for | 10 mg | Anticipated | Available | Manufacturing | 4/10/2024 |
| fluoxetine hydrochloride | Capsule, hard | 22.36 mg | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/10/2024 |
| Liraglutide | Injection, solution | 6 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 4/10/2024 |
| adrenaline (epinephrine) | Injection, solution | 1 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 4/10/2024 |
| Choriogonadotropin alfa | Injection, solution | 250 microgram | Current | Emergency Supply Only | Unexpected increase in consumer demand | 4/10/2024 |
| noradrenaline (norepinephrine) acid tartrate monohydrate | Injection, concentrated | 8 mg | Current | Limited Availability | Manufacturing | 4/10/2024 |
| topotecan hydrochloride | Injection, concentrated | 4.346 mg | Current | Unavailable | Manufacturing | 4/10/2024 |
| Rabies virus | Powder | 3.25 IU | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 4/10/2024 |
| sumatriptan succinate | Tablet, film coated | 140 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| tamsulosin hydrochloride~dutasteride | Capsule, modified release | 400 microgram~500 microgram | Current | Limited Availability | Manufacturing | 3/10/2024 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Current | Limited Availability | Manufacturing | 3/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 33.65 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| telmisartan~hydrochlorothiazide | Tablet, film coated | 80 mg~12.5 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| metformin hydrochloride | Tablet, modified release | 1000 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| betahistine dihydrochloride | Tablet | 16 mg | Resolved | Available | Manufacturing | 3/10/2024 |
| potassium clavulanate~amoxicillin trihydrate | Tablet, film coated | 148.875 mg~1006.25 mg | Resolved | Available | Manufacturing | 3/10/2024 |
| clonidine hydrochloride | Tablet | 100 microgram | Resolved | Available | Unexpected increase in consumer demand | 3/10/2024 |
| tenofovir disoproxil fumarate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| celecoxib | Capsule, hard | 100 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| apomorphine hydrochloride hemihydrate | Injection, solution | 10 mg | Current | Limited Availability | Manufacturing | 3/10/2024 |
| lacosamide | Tablet, film coated | 100 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| eftrenonacog alfa | Injection, powder for | 4000 IU | Resolved | Available | Manufacturing | 3/10/2024 |
| atorvastatin calcium trihydrate | Tablet, film coated | 86.751 mg | Anticipated | Available | Manufacturing | 3/10/2024 |
| trimethoprim | Tablet, uncoated | 300 mg | Anticipated | Available | Manufacturing | 3/10/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| indometacin | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| mycophenolate mofetil | Suspension | 200 mg/mL | Resolved | Available | Manufacturing | 3/10/2024 |
| levothyroxine sodium | Tablet, uncoated | .075 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| levothyroxine sodium | Tablet, uncoated | .2 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/10/2024 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/10/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/10/2024 |
| celecoxib | Capsule, hard | 100 mg | Resolved | Available | Manufacturing | 3/10/2024 |
| norethisterone acetate~estradiol | Drug delivery system, transdermal | 2.7 mg~.62 mg | Current | Unavailable | Manufacturing | 3/10/2024 |
| amoxicillin trihydrate | Tablet, film coated | 1148 mg | Resolved | Available | Manufacturing | 3/10/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Anticipated | Available | Manufacturing | 3/10/2024 |
| nizatidine | Capsule | 150 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/10/2024 |
| lisinopril dihydrate | Tablet, uncoated | 10.89 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| escitalopram oxalate | Tablet, film coated | 25.56 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| topiramate | Tablet, film coated | 200 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| zolpidem tartrate | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| isoniazid | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| gliclazide | Tablet, modified release | 30 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 2/10/2024 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Limited Availability | Manufacturing | 2/10/2024 |
| risperidone | Tablet, film coated | 4 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| donepezil hydrochloride | Tablet, film coated | 5 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 2/10/2024 |
| hydrocortisone sodium succinate | Injection, powder for | 334.25 mg | Current | Limited Availability | Manufacturing | 2/10/2024 |
| bicalutamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| quetiapine fumarate | Tablet, film coated | 115.12 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| quetiapine fumarate | Tablet, film coated | 345.36 mg | Current | Limited Availability | Manufacturing | 2/10/2024 |
| simvastatin | Tablet, film coated | 80 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Limited Availability | Manufacturing | 2/10/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 2/10/2024 |
| atomoxetine hydrochloride | Capsule, hard | 45.5 mg | Current | Unavailable | Manufacturing | 2/10/2024 |
| fluconazole | Capsule, hard | 200 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| phenytoin sodium | Capsule, hard | 100 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| lacosamide | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| risperidone | Oral Liquid, solution | 1 mg/mL | Resolved | Available | Manufacturing | 2/10/2024 |
| teriflunomide | Tablet, film coated | 14 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| pregabalin | Capsule, hard | 75 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| pregabalin | Capsule, hard | 75 mg | Anticipated | Available | Manufacturing | 2/10/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 54 mg | Current | Unavailable | Manufacturing | 2/10/2024 |
| captopril | Tablet, uncoated | 25 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| captopril | Tablet, uncoated | 50 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| indapamide hemihydrate | Tablet | 2.5 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Resolved | Available | Manufacturing | 2/10/2024 |
| rasagiline mesilate | Tablet | 1.56 mg | Current | Limited Availability | Manufacturing | 1/10/2024 |
| Rabies virus | Injection, powder for | 2.5 IU | Resolved | Available | Manufacturing | 1/10/2024 |
| prasugrel | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 1/10/2024 |
| spironolactone | Tablet, uncoated | 100 mg | Resolved | Available | Manufacturing | 1/10/2024 |
| sugammadex sodium | Injection, solution | 217.6 mg | Resolved | Available | Commercial Changes / Commercial viability | 1/10/2024 |
| Follitropin beta | Injection, solution | 833 IU/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/10/2024 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Current | Limited Availability | Manufacturing | 1/10/2024 |
| Peginterferon alfa2a | Injection, solution | 135 microgram | Anticipated | Available | Unexpected increase in consumer demand | 1/10/2024 |
| Peginterferon alfa2a | Injection, solution | 180 microgram | Anticipated | Available | Unexpected increase in consumer demand | 1/10/2024 |
| pimecrolimus | Cream | 10 mg/g | Current | Limited Availability | Manufacturing | 1/10/2024 |
| griseofulvin | Tablet, uncoated | 125 mg | Current | Unavailable | Manufacturing | 30/09/2024 |
| sodium pyrophosphate | Injection, powder for | 30 mg | Current | Limited Availability | Manufacturing | 30/09/2024 |
| hydrocortisone sodium succinate | Injection, powder for | 134 mg | Resolved | Available | Manufacturing | 30/09/2024 |
| cefepime hydrochloride monohydrate | Injection, powder for | 1189.2 mg | Anticipated | Available | Manufacturing | 30/09/2024 |
| lacosamide | Tablet, film coated | 100 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 30/09/2024 |
| lacosamide | Tablet, film coated | 150 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 30/09/2024 |
| heparin sodium | Injection, solution | 5000 IU/mL | Current | Limited Availability | Manufacturing | 30/09/2024 |
